EAU Guidelines on Urinary Incontinence

Thüroff, Joachim W.; Abrams, Paul; Andersson, Karl‐Erik; Artibani, Walter; Chapple, Christopher R.; Drake, Marcus; Hampel, Christian; Neisius, Andreas; Schröder, Annette; Tubaro, Andrea

doi:10.1016/j.eururo.2010.11.021

Cited by 343 publications

(200 citation statements)

References 18 publications

Supporting

Mentioning

174

Contrasting

Unclassified

Order By: Relevance

“…Numerous studies show that after this treatment sleep quality increases and a significant reduction in nocturia episodes is achieved [18][19][20]. Thus, in our study there was a significant decrease in nocturnal urine volume compared to baseline, both during the first week and the control performed within three months of initiation of therapy, which led to a decrease in the number of nocturnal voids and consequently a statistically significant increase in the time to first micturition.…”

Section: Discussionmentioning

confidence: 51%

Therapeutic Efficacy and Safety of Oral Desmopressin for Nocturia in the Elderly Patient

Verdejo¹

2017

JURNOA

View full text Add to dashboard Cite

Objective: To evaluate the therapeutic efficacy and safety of using oral desmopressin in the treatment of nocturia in the elderly. Patients And Method:During the last 8 years we have treated with oral desmopressin (Minurin® 60 mcg) 118 elderly males (mean age 75 years) suffering from nocturia (mean of 5 urinations). We prospectively evaluated the micturition volume the night before and after treatment and the number of voids and the time until the first night-time micturition. Periodic analytical studies were conducted in all patients, primarily of plasma sodium levels. To assess the impact of nocturia on quality of life and satisfaction with treatment received, we used the validated nocturia-specific N-QoLquestionnaire. Results:In all patients there was a decrease in the number of nighttime micturitions from the first week of treatment, none presenting any manifestations of clinical relevance to suggest treatment side effects. No significant laboratory abnormalities were evident either, and the patients experienced significant quality of life improvement. Conclusions:Treatment with oral desmopressin is an effective and well tolerated measure in the elderly nocturia patient. It provides a significant reduction in nocturnal urine volume compared to baseline, showing a reduction in the number of night-time urinations and a prolongation of uninterrupted sleep to first void. This offers a clear improvement in patients' quality of life, with minimal likelihood of adverse effects, and we believe that its use should be included in the urologist's routine therapeutic measures.

show abstract

Section: Discussionmentioning

confidence: 51%

Therapeutic Efficacy and Safety of Oral Desmopressin for Nocturia in the Elderly Patient

Verdejo¹

2017

JURNOA

View full text Add to dashboard Cite

show abstract

“…In-vitro assessment of the AUS#1 occlusive cuff pressure (OCP) profile: (A) during a complete device cycle; and (B) during the cuff deflation. Notes: [1] "Closed" state: Initially, the pressure within the system is balanced. The cuff is full with fluid and at pressure-regulating balloon's (PRB) pressure.…”

Section: Discussionmentioning

confidence: 99%

“…1 Initially described in 1947 by Foley, 2 the concept was developed and introduced on the market in 1973 by American Medical System Holdings Inc. (Minnetonka, MN, U.S.) under the name AS721…”

Section: Introductionmentioning

confidence: 99%

Montreal electronic artificial urinary sphincters: Our futuristic alternatives to the AMS800™

Biardeau

Hached

Loutochin

et al. 2017

CUAJ

View full text Add to dashboard Cite

Introduction: We aimed to present three novel remotely controlled hydromechanical artificial urinary sphincters (AUSs) and report their in-vitro and ex-vivo results. Methods: We successively developed three distinct hydromechanical AUSs on the basis of the existing AMS800 ™ device by incorporating an electronic pump. No changes were made to the cuff and balloon. The AUS#1 was designed as an electromagnetically controlled device. The AUS#2 and AUS#3 were conceived as Bluetooth 2.1 remotely controlled and Bluetooth 4.0 remotelycontrolled, adaptive devices, respectively. In-vitro experiments profiled occlusive cuff pressure (OCP) during a complete device cycle, with different predetermined OCP. Ex-vivo experiments were performed on a fresh pig bladder with 4 cm cuff placed around the urethra. Leak point pressure with different predetermined OCP values was successively measured during cystometry via a catheter at the bladder dome. Results: Our in-vitro and ex-vivo experiments demonstrated that these three novel AUSs provided stable and predetermined OCP -within the physiological range -and completely deflated the cuff, when required, in a limited time compatible with physiological voiding cycles. Conclusions: Our three novel, remotely controlled AUSs showed promising results that should be confirmed by in-vivo experiments focusing on efficacy and safety.

show abstract

“…For patients suffering from OAB symptoms +/− urgency incontinence after prostate surgery, antimuscarinic medications have been recommended in the European Association of Urology (EAU) guidelines 38. However, antimuscarinics may cause cognitive impairment and should be avoided in patients at risk 27.…”

Section: Discussionmentioning

confidence: 99%

Integrative review on the non‐invasive management of lower urinary tract symptoms in men following treatments for pelvic malignancies

et al. 2015

View full text Add to dashboard Cite

SummaryAimTo develop a non‐invasive management strategy for men with lower urinary tract symptoms (LUTS) after treatment for pelvic cancer, that is suitable for use in a primary healthcare context.MethodsPubMed literature searches of LUTS management in this patient group were carried out, together with obtaining a consensus of management strategies from a panel of authors for the management of LUTS from across the UK.ResultsData from 41 articles were investigated and collated. Clinical experience was sought from authors where there was no clinical evidence. The findings discussed in this paper confirm that LUTS after the cancer treatment can significantly impair men's quality of life. While many men recover from LUTS spontaneously over time, a significant proportion require long‐term management. Despite the prevalence of LUTS, there is a lack of consensus on best management. This article offers a comprehensive treatment algorithm to manage patients with LUTS following pelvic cancer treatment.ConclusionBased on published research literature and clinical experience, recommendations are proposed for the standardisation of management strategies employed for men with LUTS after the pelvic cancer treatment. In addition to implementing the algorithm, understanding the rationale for the type and timing of LUTS management strategies is crucial for clinicians and patients.

show abstract

EAU Guidelines on Urinary Incontinence

Cited by 343 publications

References 18 publications

Therapeutic Efficacy and Safety of Oral Desmopressin for Nocturia in the Elderly Patient

Therapeutic Efficacy and Safety of Oral Desmopressin for Nocturia in the Elderly Patient

Montreal electronic artificial urinary sphincters: Our futuristic alternatives to the AMS800™

Integrative review on the non‐invasive management of lower urinary tract symptoms in men following treatments for pelvic malignancies

Contact Info

Product

Resources

About